NASDAQ:CRVS   Corvus Pharmaceuticals, Inc.
Leading diagonal completed, now in wave 2.

Out of all stocks biotech is probably the most susceptible to wrong Elliott wave counts because they are volatile due to news and trial results having a heavy influence on the stock. Nevertheless, this is a view of what the future may hold.
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.